A retrospective cohort study on radio/chemotherapy and survival following esophageal fistula in esophageal cancer patients with prior radiotherapy
Abstract Background/Objective Radiotherapy is a common treatment for patients with esophageal cancer. Esophageal fistula (perforation) is a serious complication in patients with advanced esophageal cancer. It is unclear how radio/chemotherapy post-fistula may affect survival in patients with maligna...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13853-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Background/Objective Radiotherapy is a common treatment for patients with esophageal cancer. Esophageal fistula (perforation) is a serious complication in patients with advanced esophageal cancer. It is unclear how radio/chemotherapy post-fistula may affect survival in patients with malignant esophageal fistulae with radiotherapy pre-fistula. We sought to evaluate radio/chemotherapy and survival post-fistula in patients with esophageal cancer and radiotherapy pre-fistula. Methods In a retrospective cohort study, we reviewed post-fistula treatments and survival in 98 patients with esophageal cancer and prior radiotherapy with or without chemotherapy between 2010/6 and 2023/5 in a regional cancer care centre in Zhengzhou, China. The primary outcome was survival time (months) post-fistula. The inverse of the probability of treatment weighting (IPTW) was applied in Cox regression models in assessing the association between post-fistula radio/chemotherapy and survival accounting for baseline clinical risk factors. Results The median survival time post-fistula was 3.5 months (inter-quartile range: 1.4–7.8 months). Compared to patients without radio/chemotherapy post-fistula, longer survival was observed in patients with radiotherapy [adjusted HR 0.40 (95% CI 0.20–0.80)], chemotherapy [adjusted HR 0.24 (0.08–0.72)], or chemo and radiotherapy [adjusted HR 0.10 (0.05–0.19)] post-fistula. Among patients with radiotherapy post-fistula, longer survival was observed in patients with both chemo and radiotherapy [adjusted HR 0.18 (0.08–0.36)] than with radiotherapy only. Conclusions In patients with malignant esophageal fistulae and radiotherapy pre-fistula, continued radiotherapy post-fistula may improve survival, and combined radio/chemotherapy may be beneficial to optimal survival. |
|---|---|
| ISSN: | 1471-2407 |